dr. richard finn on the rationale for targeting cdk4/6 with pd 0332991
Published 11 years ago • 217 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:53
dr. finn on the inhibition of cdk 4/6 in breast cancer
-
1:05
dr. richard finn on pd 0332991 plus letrozole in er-positive breast cancer
-
1:34
dr. richard finn on the future of palbociclib in breast cancer
-
1:06
dr. finn on the potential of cdk inhibition
-
1:20
dr. finn on new cdk 4/6 inhibitors for breast cancer
-
7:13
the biological rationale for cdk4/6 inhibitors
-
2:28
finn: targeting cdk 4/6 in breast cancer
-
1:41
dr. richard finn describes the phase iii trial of palbociclib for breast cancer
-
14:33
(ap biology) cell cycle regulation - cyclins, cdks, p53, and cancer
-
21:54
lee hartwell (fred hutch): understanding the cell cycle regulators
-
5:16
the clinical potential of cdk4/6 inhibitors
-
2:11
dr. finn on the rationale for the phase iii keynote-240 trial in hcc
-
2:04
dr. richard finn discusses palbociclib for patients with advanced breast cancer
-
2:01
dr. finn on the revolution of cdk4/6 inhibition in hr breast cancer
-
4:43
richard s. finn, md: the combination of pd 0332991 and letrozole phase ii results
-
2:04
dr. finn on cyclin-dependent kinases and the treatment of cancer
-
1:50
dr. finn on the future of palbociclib for the treatment of breast cancer
-
1:34
dr. finn on results of resource study in liver cancer
-
2:02
latest advances in the development of cdk4/6 inhibitors in hr breast cancer
-
31:32
atlas and cdk4/6 inhibitor trials presented by dr. john smith ii, compass oncology
-
3:50
cdk4/6 inhibitors in metastatic breast cancer
-
1:55
dr. finn on treating er breast cancer patients with antiestrogens